Wisconsin is currently home to 1268 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Relapsing Multiple Sclerosis
Register for Updates
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271
Recruiting
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2025
Locations: Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Register for Updates
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/03/2025
Locations: Aurora BayCare Medical Center, Green Bay, Wisconsin
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046
Recruiting
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the abil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: University of Wisconsin Hospital & Clinics, Madison, Wisconsin
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Virtual A2 Study for At Risk Children
NCT06643598
Recruiting
The goal of this behavioral-interventional study is to learn if the Abecedarian Approach implemented virtually for children ages 0-5 with a history of Hypoxic Ischaemic Encephalopathy (HIE) and/or premature birth produces the same effects as when administered at in-person facilities.
Gender:
ALL
Ages:
5 years and below
Trial Updated:
06/02/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Hypoxic Ischaemic Encephalopathy (HIE), Premature Birth, Cerebral Palsy, Neurological Disorder
Register for Updates
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666
Recruiting
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/02/2025
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754
Recruiting
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Gender:
ALL
Ages:
All
Trial Updated:
06/02/2025
Locations: Local Institution - 0004, Madison, Wisconsin
Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
Register for Updates
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
NCT06257082
Recruiting
An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how patient and clinician video testimonial interventions (n=6) increase eye health literacy and trust in healthcare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: UW Hospital and Clinics, Madison, Wisconsin
Conditions: Diabetic Retinopathy
Register for Updates
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210
Recruiting
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Small Cell Lung Cancer
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Breast Cancer
Register for Updates
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257
Recruiting
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
06/02/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Register for Updates